Inositols in PCOS

doi:10.3390/molecules25235566

Paper

Inositols in PCOS

Published Nov 27, 2020 · Z. Kamenov, A. Gateva

Molecules

Q1 SJR score

59

Citations

1

Influential Citations

Full textSemantic Scholar

Abstract

(1) Background: Myoinositol (MI) and D-chiro-inositol (DCI) are involved in a number of biochemical pathways within oocytes having a role in oocyte maturation, fertilization, implantation, and post-implantation development. Both inositols have a role in insulin signaling and hormonal synthesis in the ovaries. (2) Methods: Literature search (with key words: inositols, myo-inositol, d-chiro-inositol, PCOS) was done in PubMed until Sept. 2020 and 197 articles were identified, of which 47 were of clinical trials (35 randomized controlled trials). (3) Results: Many studies have demonstrated that in patients with polycystic ovarian syndrome (PCOS) MI treatment improved ovarian function and fertility, decreased the severity of hyperandrogenism including acne and hirsutism, positively affected metabolic aspects, and modulated various hormonal parameters deeply involved in the reproductive axis function and ovulation. Thus treating with MI has become a novel method to ameliorate PCOS symptoms, improve spontaneous ovulation, or induce ovulation. The current review is focused on the effects of MI and DCI alone or in combination with other agents on the pathological features of PCOS with focus on insulin resistance and adverse metabolic outcomes. (4) Conclusions: The available clinical data suggest that MI, DCI, and their combination in physiological ratio 40:1 with or without other compound could be beneficial for improving metabolic, hormonal, and reproductive aspects of PCOS.

Systematic Review

Study Snapshot

Myoinositol (MI) and D-chiro-inositol (DCI) in a 40:1 ratio may improve metabolic, hormonal, and reproductive aspects of polycystic ovarian syndrome (PCOS).

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Inositols in PCOS

Sign up to use Study Snapshot

References

Altered Ovarian Inositol Ratios May Account for Pathological Steroidogenesis in PCOS

Altered ovarian myo-inositol ratios may contribute to pathological steroidogenesis in PCOS, and inositol-based treatment protocols may help manage symptoms and improve quality of life for affected women.

Fundamental Concepts and Novel Aspects of Polycystic Ovarian Syndrome: Expert Consensus Resolutions

PCOS negatively impacts reproduction, general health, sexual health, and quality of life, with early symptoms and increased risk of pregnancy-related complications; medical therapy is effective; and nutraceutical therapy may offer potential benefits.

Metabolic impact of current therapeutic strategies in Polycystic Ovary Syndrome: a preliminary study

Inositol therapies show the most benefits against PCOS symptoms, while obesity worsens lipid and glycemic metabolism, suggesting integrative treatment and calorie restriction are key for long-term management.

The effect of myo-inositol, vitamin D3 and melatonin on the oocyte quality and pregnancy in in vitro fertilization: a randomized prospective controlled trial.

Myo-inositol, melatonin, and vitamin D3 supplementation before and after ICSI treatment significantly improves oocyte quality and pregnancy rates in women undergoing in vitro fertilization.

High dose of d-chiro-inositol improves oocyte quality in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial

High doses of d-chiro-inositol combined with Myo-inositol improve oocyte cytoplasm quality in women with PCOS undergoing ICSI.

Citations

The effect of myo‐inositol supplementation on AMPK/PI3K/AKT pathway and insulin resistance in patients with NAFLD

Myo-inositol supplementation improves insulin resistance in obese patients with non-alcoholic fatty liver disease by upregulating AMPK, AKT, and PDK1 genes.

The Three Lichens: A Generalist Approach to Vulvar Skin Conditions

Vulvar skin conditions are under-recognized in healthcare training programs, limiting providers' ability to assess and manage them, resulting in poor patient care in Canada.

A bitter pill to swallow: adjustments to oral contraceptive pill use in polycystic ovary syndrome.

Tailoring oral contraceptive pill use for women with PCOS can improve management and reduce complications, while avoiding generalized use and considering metabolic factors.

Management of Polycystic Ovarian Syndrome: Looking Beyond the Ovaries

Polycystic ovarian syndrome (PCOS) is a complex metabolic and reproductive syndrome with consequences beyond ovarian dysfunction, affecting 1.4 million Canadians and beginning in utero.

The Potential for Ketogenic Diets to Control Glucotoxicity, Hyperinsulinemia, and Insulin Resistance to Improve Fertility in Women with Polycystic Ovary Syndrome

Ketogenic diets can help manage insulin resistance and glucotoxicity in women with PCOS, improving fertility and promoting menstrual regularity.

d-Chiro-Inositol in Clinical Practice: A Perspective from the Experts Group on Inositol in Basic and Clinical Research (EGOI)

D-chiro-inositol shows potential in treating various metabolic and gynecological disorders by acting as an insulin sensitizer, inhibiting aromatase transcription, and modulating white adipose tissue/brown adipose tissue transdifferentiation.